Evaluation of serum bactericidal activity specific for Neisseria meningitidis serogroup A and B: Effect of Immunization with Neisseria meningitidis serogroup A polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate

Research Journal of Microbiology

Volumn 2, Issue 5, 2007, Pages 436-444

  Siadat, Seyed Davar ^a   Behzadiyannejad, Q ^b   Tabaraie, B ^a   Ahmadi, H ^a   Norouzian, D ^a   Pirayeeh, S N ^b   Nejati, M ^a   Zangeneh, M ^c  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Conjugate vaccine; Neisseria meningitidis serogroup A and B; OMV; Serum bactericidal activity

Indexed keywords

BACTERIA (MICROORGANISMS); NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS SEROGROUP A; OAT MOSAIC VIRUS; ORYCTOLAGUS CUNICULUS;

EID: 34547887710     PISSN: 18164978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Ada, G. and D. Isaacs, 2003. Carbohydrate-protein conjugate vaccine. Clin. Microbiol. Infect., 9: 79-85.
2. Anderson, E.L., T. Bowers, C.M. Mink, D.J. Kendy, R.B. Belshe, H. Harakeh, L. Pais, P. Holder and G.M. Carlone, 1994. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immunol., 62: 3391-3395.
3. Anonymous, 1995. Pyrogen Test, In: United States Pharmacopoeia 23rd, (1995) Revision, U.S. Pharmacopoeial Convention Inc., Rockville, M.D., D.1718.
4. Arigita, C., W. Jiskoot and J. Westdijk et al., 2004. Stability of mono-and trivalent meningococcal outer membrane vesicle vaccines. Vaccine, 22: 629-642.
5. Balmer, P. and R. Borrow, 2004. Serologic correlates of protection for evaluating the response to meningococcal vaccine. Expert Rev. Vaccines, 3: 77-87.
6. Berry, D.C., A. Van Den Kaaden, C.E. Frasch and A.B. Leussink, 2002. Effect of acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune response. Infect. Immunol., 70: 3707-3713.
7. Bethell, D. and A.J. Pollard, 2002. Meningococcal vaccines. Expert Rev. Vaccines, 1: 75-83.
8. Cartwright, K., R. Morris, H. Rümke, A. Fox, R. Borrow, N. Begg, P. Richmond and J. Poolman, 1999. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane protein. Vaccine, 17: 2612-2619.
9. Cartwright, K., 2001. Meningococcal disease in Europe: Epidemiology, mortality and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. Vaccine, 19: 4347-4356.
10. Claassen, I., J. Meylis, P. Ley, C. Peeters, H. Brons, J. Robert, D. Borsboom, A. Ark, I. Straaten, P. Roholl, B. Kuipers and J. Poolman, 1996. Production, characterization and control of Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicles vaccine. Vaccine, 14: 1001-1008.
11. Costantino, P., F. Norelli, A. Giannozzi, S.D. Ascenzi, A. Bartoloni, S. Kaur, D. Tang, R. Seid, S. Viti, R. Paffetti, M. Bigio, C. Pennatini, G. Averani, V. Guarnieri, E. Gallo, N. Ravenscroft, C. Lazzeroni, R. Rappuoli and C. Ceccarini, 1999. Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines. Vaccine, 17: 1251-1263.
12. Fukasawa, L.O., M.C. Gorla, R.P. Schekman, L.R. Garcia, S.M. Carneiro, I. Raw and M.M. Tanizaki, 1999. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate. Vaccine, 17: 2951-2958.
13. Fukasawa, L.O., W.O. Dias, R.P.F. Schenkman, I. Raw and M.M. Tanizaki, 2004. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroup B/C in neonatal mice. FEMS Immunol. Med. Microbiol., 41: 205-210.
14. Gudlavalleti, S.K., A.K. Datta, Y.L. Tzeng, C. Noble, R.W. Carlson and D.S. Stephens, 2004. The Neisseria meningitidis serogroup A capsular polysaccharide O-3 and O-4 acetyltransferase. J. Biol. Chem., 279: 42765-42773.
15. Gupta, R.K., W. Egan, D.A. Bryla, J.B. Robbins and S. Szu, 1995. Comparative immunogenicity of conjugates composed of Escherichia coli 0111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazin, bound to tetanus toxoid by two synthetic schemes. Infect. Immunol., 63: 2805-2810.
16. Hestrin, S., 1949. The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamin and it's analytical application. J. Biol. Chem., 180: 249-261.
17. Holst, J., B. Feiring, J.E. Fuglesang, E.A. Høiby, H. Nøkleby, I.S. Aaberge and E. Rosenqvist, 2003. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine, 21: 734-737.
18. Hossany, R.B., M.A. Johanson, A.A. Eniade and B.M. Pinto, 2004. Synthesis and immunochemical characterization of protein conjugates of carbohydrate and carbohydrate-mimic peptides as experimental vaccines. Bio. Org. Medic Chem., 12: 3743-3754.
19. Jennings, H.J. and C. Lugowski, 1981. Immunochemistry of groups A, B and C meningococcal polysaccharide tetanus toxoid conjugates. J. Immunol., 27: 1011-1018.
20. Jensen, C., B. Kuipers, J. Van Der Bienzen, H. Cock, P. Van Der Ley and J. Tommassen, 2000. Immunogenicity of in vitro folded outer membrane protein PorA of Neisseria meningitidis. FEMS Immunol. Med. Microbiol., 27: 227-233.
21. Jin, Z., C. Chu, J.B. Robbins and R. Schneerson, 2003. Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice. Infect. Immunol., 71: 5115-5120.
22. Jodar, L., K. Cartwright and I.M. Feavers, 2000. Standardisation and vialidation of serological assay for the evaluation of immune responses to Neisseria meninngitidis serogroup A and C vaccines. Biologicals, 28: 193-197.
23. Jodar, L., I.M. Feavers, D. Salisbury and D.M. Granof, 2002. Development of vaccines against meningococcal disease. Lancet, 359: 1499-1508.
24. Lesinski, G.B. and M.A. Westerlink, 2001. Novel vaccine strategies to T-independent antigens. J. Microbiol. Meth., 47: 135-149.
25. Lindberg, A.A., 1999. Glycoprotein conjugate vaccines. Vaccine, 17: 28-36.
26. Liu, T.Y., E.C. Gotschlich, E.K. Jonssen and J.R. Wysocki, 1971. Studies on the meningococcal polysaccharides. J. Biol. Chem., 246: 2849-2858.
27. Milagres, L.G., M.C.A. Gorla and C.T. Sacchi, 1998. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with a outer membrane vaccine. Infect. Immunol., 66: 4755-4761.
28. Mond, J.J., A. Lees and C.M. Snapper, 1995. T-cell independent antigens type 2. Ann. Rev. Immunol., 13: 655-692.
29. Norheim, G., A. Aase, D.A. Caugant, E.A. Hoiby, E. Eritzsonn, T. Tangen, P. Kristiansen, U. Heggelund and E. Rosenqvist, 2005. Development and characterization of outer membrane vesicle vaccines against serogroup A Neisseria meningitids. Vaccine, 23: 3762-3774.
30. Peeters, C., I. Claassen, M. Schuller, G.F.A. Kersten, Van Der Voort and J.T. Poolman, 1999. Immunogenicity of various presentation forms of PorA outer membrane protein of Neisseria meningitidis in mice. Vaccine, 17: 2702-2712.
31. Perez-Melgosa, M., H.D. Ochs and P.S. Linsley, 2001. Carrier-mediated enhancement of cognate T cell help: The basis for enhanced immunogenicity of meningoccocal outer membrane protein polysaccharide conjugate vaccine. Eur. J. Immunol., 1 31: 2373-2381.
32. Peterson, G.L., 1977. A simpilification of the protein assay of Lowry et al. Which is more generally applicable. Anal. Biochem., 83: 346-356.
33. Rosenstin, N.E., B.A. Perkins, D.S. Stephens, T. Popovic and J.M. Hughes, 2001. Meningococcal disease. N. Eng. J. Med., 344: 1378-1388.
34. Ruggeberg, J.U. and A.J. Pollard, 2004. Meningococcal vaccines. Pediat Drugs, 6: 251-266.
35. Schmidt, S., D. Zhu, V. Barniak, K. Mason, Y. Zahang, R. Arumugham and T. Metcalf, 2001. Passive immunization with Neisseria meningitidis PorA specific immune sera reduces nasopharyngeal colonization of group B meningococcus in an infant rat nasal challenge model. Vaccine, 19: 4851-4858.
36. Schneerson, R., O. Barrera, A. Sutton and J.B. Robbins, 1980. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide protein conjugates. J. Expert. Med., 152: 361-376.
37. Siadat, S.D., Q. Behzadiyannejad, B. Tabaraie, H. Ahmadi and M. Nejati, 2006a. Extraction and Molecular Evaluation of Neisseria meningitidis Serogroup B Outer Membrane Vesicle Containing PorA. Danshvar, 64: 57-64.
38. Siadat, S.D., B. Tabaraie, H. Ahmadi, D. Norouziuan and Q. Behzadian-Nejad et al., 2006b. Evaluation of Serum Bactericidal Activity Specific for Neisseria meningitidis Serogroup A and B Effect of Immunization with Neisseria meningitidis SerogroupA Polysaccharide and Serogroup B Outer Membrane Vesicle Conjugate as a Bivalent Meningococcus Vaccine Candidate. In Proceedings of The First International Congress of Central Asia Infectious Disease. October 30-November 03, Bishkek, Kyrgyzestan.
39. Vella, P.P., J.M. Staub, J. Armstrong and K.T. Dolan et al., C.R. Rusk, 1990. Immunogenicity a new Haemophilus influenzae type b conjugate vaccine (Meningococcal protein conjugate) (Pedvax HIB). Pediatrics, Supplement pp: 668-675.
40. World Health Organization, 1976. Requirements for meningococcal polysaccharide vaccine. World Health Organ. Tech. Rep. Ser., 594: 50-75.